SCHEMBL12243166

SCHEMBL12243166

CC(=O)c1ccc(CCc2ccc(-c3ccc4ccccc4c3)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
LMNA P02545 3/20 0.49
MMP12 P39900 1/20 0.48
MMP13 P45452 1/20 0.48
ESR1 P03372 1/20 0.47
ESR2 Q92731 1/20 0.47
ALDH1A1 P00352 3/20 0.47
HPGD P15428 2/20 0.46
HSD17B1 P14061 2/20 0.46
KDM4E B2RXH2 1/20 0.46
KMT2A Q03164 3/20 0.46
GAA P10253 1/20 0.46
HSD17B10 Q99714 1/20 0.45
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
PTGES O14684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12243167 0.91 MAPT (0.59) MAPTSMN1; SMN2LMNAMMP12MMP13
SCHEMBL12243162 0.91 MAPT (0.54) MAPTSMN1; SMN2LMNAMMP12MMP13
SCHEMBL18260221 0.90 MAPT (0.64) MAPTSMN1; SMN2LMNAESR1ESR2
SCHEMBL12243165 0.89 MAPT (0.51) MAPTSMN1; SMN2LMNAMMP12MMP13
SCHEMBL2349393 0.86 PTGES (0.58) MAPTESR1ESR2ALDH1A1KMT2A
SCHEMBL2355805 0.84 PLAU (0.56) ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL7741913 0.83 MAPT (0.70) MAPTSMN1; SMN2LMNAMMP12MMP13
SCHEMBL1293873 0.79 MAPT (0.57) MAPTSMN1; SMN2LMNAALDH1A1HPGD
SCHEMBL2354635 0.79 PLAU (0.53) PTGESALOX5
SCHEMBL14330470 0.79 KMT2A (0.64) MAPTSMN1; SMN2LMNAMMP12MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921309-B2 Lipopeptide compounds and their use UNIQUEST PTY LIMITED (AU) 2014-12-30 US disclosed
US-8921309-B2 Lipopeptide compounds and their use UNIQUEST PTY LIMITED (AU) 2014-12-30 US disclosed
EP-2350119-B1 LIPOPEPTIDE COMPOUNDS AND THEIR USE UNIQUEST PTY LTD (AU) 2014-10-29 EP disclosed
US-20110224129-A1 Lipopeptide Compounds and Their Use MERLION PHARMACEUTICALS PTE LTD (SG) 2011-09-15 US disclosed
US-20110224129-A1 Lipopeptide Compounds and Their Use MERLION PHARMACEUTICALS PTE LTD (SG) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224129-A1 Lipopeptide Compounds and Their Use VIP, LTA, CLPTM1 MAPT 4432/4885SMN1; SMN2 4169/4885LMNA 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.